Schroder Investment Management Group Acquires 82,601 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Schroder Investment Management Group raised its stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 111.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 156,874 shares of the company's stock after purchasing an additional 82,601 shares during the quarter. Schroder Investment Management Group owned 0.30% of Janux Therapeutics worth $8,236,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in JANX. Pictet Asset Management Holding SA bought a new stake in Janux Therapeutics during the 4th quarter valued at $20,602,000. JPMorgan Chase & Co. increased its position in shares of Janux Therapeutics by 941.8% in the fourth quarter. JPMorgan Chase & Co. now owns 191,603 shares of the company's stock valued at $10,258,000 after acquiring an additional 173,211 shares during the period. EntryPoint Capital LLC bought a new position in shares of Janux Therapeutics during the fourth quarter valued at about $655,000. Vanguard Group Inc. boosted its holdings in shares of Janux Therapeutics by 15.6% during the fourth quarter. Vanguard Group Inc. now owns 2,136,332 shares of the company's stock worth $114,379,000 after purchasing an additional 288,402 shares during the period. Finally, LPL Financial LLC bought a new stake in shares of Janux Therapeutics in the fourth quarter worth about $439,000. Hedge funds and other institutional investors own 75.39% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Scotiabank dropped their price objective on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a report on Friday, February 28th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $200.00 price target on shares of Janux Therapeutics in a report on Wednesday, December 11th. Wedbush restated an "outperform" rating and issued a $76.00 price objective (up from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. William Blair reaffirmed an "outperform" rating on shares of Janux Therapeutics in a research note on Friday, January 10th. Finally, HC Wainwright reissued a "buy" rating and issued a $70.00 price target on shares of Janux Therapeutics in a research note on Monday, March 3rd. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $92.44.

Insider Activity at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 3,334 shares of the firm's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $32.15, for a total transaction of $107,188.10. Following the sale, the insider now owns 82,139 shares of the company's stock, valued at $2,640,768.85. This trade represents a 3.90 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Ra Capital Management, L.P. purchased 110,206 shares of Janux Therapeutics stock in a transaction dated Friday, March 7th. The stock was bought at an average price of $31.02 per share, with a total value of $3,418,590.12. Following the completion of the purchase, the director now directly owns 10,141,287 shares of the company's stock, valued at approximately $314,582,722.74. This trade represents a 1.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 29.40% of the stock is owned by insiders.

Janux Therapeutics Trading Up 12.8 %

Janux Therapeutics stock traded up $3.04 during mid-day trading on Wednesday, hitting $26.83. The company had a trading volume of 2,840,388 shares, compared to its average volume of 867,719. Janux Therapeutics, Inc. has a 12 month low of $22.52 and a 12 month high of $71.71. The stock's 50 day moving average price is $32.28 and its two-hundred day moving average price is $44.44. The company has a market capitalization of $1.59 billion, a PE ratio of -22.93 and a beta of 3.27.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Equities research analysts anticipate that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.